Kiniksa Pharmaceuticals Ltd. Class A (KNSA) has disclosed a new risk, in the Capital Markets category.
Kiniksa Pharmaceuticals Ltd. Class A faces significant risks associated with exchange rate fluctuations, which could materially affect its financial condition and results of operations. As the company operates internationally, its assets, earnings, and cash flows are subject to currency movements, especially between the U.S. dollar, euro, British pound, and Swiss franc. The predominance of U.S. dollar transactions within the company contrasts with the location of its parent company and subsidiaries outside the U.S., which may incur expenses in foreign currencies. This exposure to foreign currency volatility poses a potential challenge, impacting reported financial outcomes and cash flows across different periods.
Overall, Wall Street has a Strong Buy consensus rating on KNSA stock based on 4 Buys.
To learn more about Kiniksa Pharmaceuticals Ltd. Class A’s risk factors, click here.
